Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Oncol. Mar 15, 2013; 5(3): 43-49
Published online Mar 15, 2013. doi: 10.4251/wjgo.v5.i3.43
Published online Mar 15, 2013. doi: 10.4251/wjgo.v5.i3.43
Reference | Epimutations in genes found in colon cancer (mechanism) | Percentage of the sporadic cancers with that epimutation | Epimutations in genes in field defect (mechanism) | Percentage of the field defect with that epimutation |
Agrelo et al[31] | WRN (CGI) | 38% | ||
Shen et al[32] | MGMT (CGI) | 46% | MGMT (CGI) | 23% |
Psofaki et al[33] | MGMT (CGI) | 90% | ||
Psofaki et al[33] | MLH1 (CGI) | 65% | ||
Truninger et al[29] | MLH1 (CGI) | 96% | ||
Lee et al[34] | MLH1 (CGI) | 2% | ||
Lee et al[34] | MSH2 (CGI) | 13% | MSH2 (CGI) | 5% |
Lee et al[34] | MGMT (CGI) | 47% | MGMT (CGI) | 11% |
Facista et al[35] | ERCC1 | 100% | ERCC1 | 60% |
Facista et al[35] | PMS2 | 88% | PMS2 | 50% |
Facista et al[35] | XPF | 55% | XPF | 40% |
- Citation: Bernstein C, Nfonsam V, Prasad AR, Bernstein H. Epigenetic field defects in progression to cancer. World J Gastrointest Oncol 2013; 5(3): 43-49
- URL: https://www.wjgnet.com/1948-5204/full/v5/i3/43.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v5.i3.43